Shionogi (4507.T): Announces acquisition of IntraBio, a developer of rare disease treatments

Goldman Sachs published a note on Shionogi (4507.T). Shionogi announced at 3pm JST on October 5 that it plans to acquire 100% of the shares in US-based IntraBio for US$2 bn, with the transaction expected to close in November-December 2026. IntraBio possesses strong R&D capabilities in rare neurodegenerative and inherited neurological diseases, and has launched Aqneursa, which received FDA approval in September 2024 as a treatment for neurological manifestations associated with Niemann-Pick disease type C and in September 2026 as a treatment for ataxia in patients with ataxia-telangiectasia (A-T). In FY12/25, IntraBio recorded sales of US$68 mn and an operating loss of US$35 mn. Shionogi completed its acquisition of ALS treatment Radicava in April 2026 and aims to leverage the IntraBio acquisition to secure rare-disease products as well as expertise (talent and know-how) to drive the expansion of its business footprint. Goldman Sachs is Not Rated on Shionogi.